4-26-12-Shares of Repligen (NASDAQ:RGEN) are trading over 45% lower after trading resumed in the shares that were halted on news that biotechnology firm would be asked for more information on its pancreatic imaging treatment by the FDA.The FDA, which was due to decide whether to approve the drug by June 21st, canceled a May meeting of advisers to review the compound, RG1068, the company said in a statement today.The Massachusetts-based firm expects regulators will request additional data on the drug.SmarTrend is bullish on shares of Repligen and our subscribers were alerted to buy on January 25, 2012 at $3.69. The stock has risen 14.7% since the alert was issued.
